Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPIcorn: Capivasertib plus endocrine therapy in HR+/HER2- advanced breast cancer
2024-511392-15-00Phase 3Authorised
- Sponsor
- Westdeutsche Studiengruppe
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of capivasertib in breast cancer, sponsored by Westdeutsche Studiengruppe. Primary endpoints: TTNT1 superiority vs standard curve and PRO-adherence vs non-adherence on TTDQoL. Planned start May 2025; status: authorised.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-511392-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511392-15-00.